Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 21 to 30 of 628 total matches.
Vaccination Recommendations for Bivalent mRNA COVID-19 Vaccines (online only)
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
Not Previously Vaccinated
Previously Vaccinated with Monovalent Vaccine2
Previously Received ?1 Bivalent Dose3 ...
View the Vaccination Recommendations for Bivalent mRNA COVID-19 Vaccines
Med Lett Drugs Ther. 2023 May 1;65(1675):e1 doi:10.58347/tml.2023.1675f | Show Introduction Hide Introduction
Vuity - Pilocarpine Ophthalmic Solution for Presbyopia
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022 (Issue 1643)
Vuity - Pilocarpine Ophthalmic Solution for Presbyopia
The FDA has approved Vuity (Abbvie), a 1 ...
The FDA has approved Vuity (Abbvie), a 1.25%
ophthalmic solution of the muscarinic receptor
agonist pilocarpine hydrochloride, for treatment of
presbyopia in adults. Pilocarpine 1%, 2%, and 4%
ophthalmic solutions (Isopto Carpine, and others)
have been available for years for treatment of
glaucoma, but local and systemic adverse effects
have limited their use.
COVID-19 Update: FDA Expands Bivalent Vaccine Use, Revises Vaccination Schedules
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 5063)
authorized for use in the US.1
All persons ≥6 months old who completed a primary
series with the Pfizer ...
The FDA has amended its Emergency Use Authorizations
(EUAs) for the bivalent mRNA COVID-19 vaccines
(original and Omicron BA.4/5 strains) manufactured by
Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax)
to permit their use for all doses administered to persons
≥6 months old. The monovalent Pfizer and Moderna
vaccines are no longer authorized for use in the US
Med Lett Drugs Ther. 2023 May 1;65(5063):1 doi:10.58347/tml.2023.5063a | Show Introduction Hide Introduction
Clascoterone Cream (Winlevi) for Acne
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021 (Issue 1640)
not respond to topical combination therapy, addition
of an oral tetracycline is recommended.1,2 The most ...
The FDA has approved Winlevi (Sun), a 1% cream
formulation of the androgen receptor inhibitor
clascoterone, for treatment of acne vulgaris in
patients ≥12 years old. It is the first topical androgen
receptor inhibitor to be approved by the FDA.
Tirzepatide (Mounjaro) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022 (Issue 1654)
-like peptide-1 (GLP-1)
receptors, to improve glycemic control in adults
with type 2 diabetes ...
The FDA has approved tirzepatide (Mounjaro –
Lilly), a peptide hormone with activity at both
glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1)
receptors, to improve glycemic control in adults
with type 2 diabetes. Tirzepatide, which is injected
subcutaneously once weekly, is the first dual GIP/GLP-1 receptor agonist to become available in the
US. Selective GIP receptor agonists are not available
in the US; GLP-1 receptor agonists have been
available for years.
In Brief: Higher-Dose Semaglutide (Ozempic) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
peptide-1 (GLP-1) receptor agonist semaglutide
(Ozempic) for treatment of type 2 diabetes in adults ...
The FDA has approved a higher-dose injectable
formulation of the long-acting glucagon-like
peptide-1 (GLP-1) receptor agonist semaglutide
(Ozempic) for treatment of type 2 diabetes in adults.
A single SC injection of the new 8 mg/3 mL
formulation delivers 2 mg of semaglutide.
Tirzepatide (Zepbound) for Chronic Weight Management
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
The injectable glucose-dependent insulinotropic
polypeptide (GIP)/glucagon-like peptide-1 (GLP-1)
receptor ...
The injectable glucose-dependent insulinotropic
polypeptide (GIP)/glucagon-like peptide-1 (GLP-1)
receptor agonist tirzepatide, which was approved by
the FDA as Mounjaro for treatment of type 2 diabetes
in 2022, has now been approved as Zepbound (Lilly)
for chronic weight management in adults who have
a BMI ≥30 kg/m2 or a BMI ≥27 kg/m2 and at least
one weight-related comorbidity. The injectable
GLP-1 receptor agonists liraglutide (Saxenda) and
semaglutide (Wegovy) are approved for chronic
weight management in patients ≥12 years...
Med Lett Drugs Ther. 2023 Dec 25;65(1692):205-7 doi:10.58347/tml.2023.1692c | Show Introduction Hide Introduction
In Brief: OTC Alcaftadine (Lastacaft Once Daily Relief) for Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
antihistamine to be approved for over-the counter
(OTC) use (see Table 1).
Ophthalmic H1-antihistamines ...
The ophthalmic H1-antihistamine alcaftadine 0.25%,
which has been available by prescription since 2011
for use in patients with allergic conjunctivitis, is now
available without a prescription as Lastacaft Once
Daily Relief (Allergan) for temporary relief of itchy eyes
due to pollen, ragweed, grass, animal hair, and dander
in adults and children ≥2 years old. It is the third
ophthalmic antihistamine to be approved for over-the-counter
(OTC) use (see Table 1).
A New Indication for Semaglutide (Wegovy)
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide (Wegovy) has been
approved by the FDA ...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide (Wegovy) has been
approved by the FDA to reduce the risk of major
adverse cardiovascular events (MACE) in adults with
established cardiovascular disease (CVD) and either
obesity or overweight. Semaglutide is the first drug
to be approved for cardiovascular risk reduction in
this population. It is also approved in a lower-dose
injectable formulation as Ozempic and in an oral
formulation as Rybelsus (see Table 1).
Med Lett Drugs Ther. 2024 Apr 29;66(1701):66-7 doi:10.58347/tml.2024.1701b | Show Introduction Hide Introduction
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
older patients.1
Metformin is generally preferred for initial treatment
of type 2 diabetes ...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of <7% while minimizing hypoglycemia
is recommended to prevent microvascular complications
of diabetes (retinopathy, nephropathy, and
neuropathy). An A1C target of <8% may be appropriate
for some older patients.